Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Tomato Extract May Help Lower Blood Pressure
- Study Indicates That Lyc-O-Mato® Reduces Blood Pressure
Randomized double blind, placebo controlled crossover trial, conducted at Ben-Gurion University, Israel, indicated that a daily intake of tomato extract Lyc-O-Mato® in soft gel capsules was associated with a significant drop in both systolic and diastolic blood pressure after eight weeks of supplementation of a normal diet.
- Study Indicates That Lyc-O-Mato® Reduces Blood Pressure
Randomized double blind, placebo controlled crossover trial, conducted at Ben-Gurion University, Israel, indicated that a daily intake of tomato extract Lyc-O-Mato® in soft gel capsules was associated with a significant drop in both systolic and diastolic blood pressure after eight weeks of supplementation of a normal diet.
- Study Indicates That Lyc-O-Mato® Reduces Blood Pressure
Randomized double blind, placebo controlled crossover trial, conducted at Ben-Gurion University, Israel, indicated that a daily intake of tomato extract Lyc-O-Mato® in soft gel capsules was associated with a significant drop in both systolic and diastolic blood pressure after eight weeks of supplementation of a normal diet.
- Study Indicates That Lyc-O-Mato® Reduces Blood Pressure
Randomized double blind, placebo controlled crossover trial, conducted at Ben-Gurion University, Israel, indicated that a daily intake of tomato extract Lyc-O-Mato® in soft gel capsules was associated with a significant drop in both systolic and diastolic blood pressure after eight weeks of supplementation of a normal diet.
- Study Indicates That Lyc-O-Mato® Reduces Blood Pressure
Randomized double blind, placebo controlled crossover trial, conducted at Ben-Gurion University, Israel, indicated that a daily intake of tomato extract Lyc-O-Mato® in soft gel capsules was associated with a significant drop in both systolic and diastolic blood pressure after eight weeks of supplementation of a normal diet.
- Dr. Navindra Seeram to speak on pomegranate bioavailability at Supplyside West
Dr. Navindra Seeram, Assistant Director of the University of California Los Angeles (UCLA) Center for Human Nutrition, will present “Are Polyphenols from Pomegranates, Strawberries and Tea Bioavailable in Human and Animal Blood and Tissues?” on Friday, November 11, at 10 am during the Educational Sessions of Supplyside West, Las Vegas.
- Dr. Navindra Seeram to speak on pomegranate bioavailability at Supplyside West
Dr. Navindra Seeram, Assistant Director of the University of California Los Angeles (UCLA) Center for Human Nutrition, will present “Are Polyphenols from Pomegranates, Strawberries and Tea Bioavailable in Human and Animal Blood and Tissues?” on Friday, November 11, at 10 am during the Educational Sessions of Supplyside West, Las Vegas.
- Study Suggests Metagenics' FirstLine Therapy Lifestyle Program Better Than AHA Diet to Reduce Cardiovascular Disease Risks in Postmenopausal Women
February issue of the journal Nutrition (Vol. 22(2), pp. 104-113) features the results of a 2-arm prospective clinical trial in postmenopausal women at risk for cardiovascular disease (CVD), suggesting that patients exhibited a greater improvement in established cardiovascular health markers when comparing Metagenics' FirstLine Therapy(R) therapeutic lifestyle program (FLT) -- to a standard American Heart Association dietary plan (AHAD) and exercise.
- Study Suggests Metagenics' FirstLine Therapy Lifestyle Program Better Than AHA Diet to Reduce Cardiovascular Disease Risks in Postmenopausal Women
February issue of the journal Nutrition (Vol. 22(2), pp. 104-113) features the results of a 2-arm prospective clinical trial in postmenopausal women at risk for cardiovascular disease (CVD), suggesting that patients exhibited a greater improvement in established cardiovascular health markers when comparing Metagenics' FirstLine Therapy(R) therapeutic lifestyle program (FLT) -- to a standard American Heart Association dietary plan (AHAD) and exercise.
- Study Suggests Metagenics' FirstLine Therapy Lifestyle Program Better Than AHA Diet to Reduce Cardiovascular Disease Risks in Postmenopausal Women
February issue of the journal Nutrition (Vol. 22(2), pp. 104-113) features the results of a 2-arm prospective clinical trial in postmenopausal women at risk for cardiovascular disease (CVD), suggesting that patients exhibited a greater improvement in established cardiovascular health markers when comparing Metagenics' FirstLine Therapy(R) therapeutic lifestyle program (FLT) -- to a standard American Heart Association dietary plan (AHAD) and exercise.
- Study Suggests Metagenics' FirstLine Therapy Lifestyle Program Better Than AHA Diet to Reduce Cardiovascular Disease Risks in Postmenopausal Women
February issue of the journal Nutrition (Vol. 22(2), pp. 104-113) features the results of a 2-arm prospective clinical trial in postmenopausal women at risk for cardiovascular disease (CVD), suggesting that patients exhibited a greater improvement in established cardiovascular health markers when comparing Metagenics' FirstLine Therapy(R) therapeutic lifestyle program (FLT) -- to a standard American Heart Association dietary plan (AHAD) and exercise.
- Study Suggests Metagenics' FirstLine Therapy Lifestyle Program Better Than AHA Diet to Reduce Cardiovascular Disease Risks in Postmenopausal Women
February issue of the journal Nutrition (Vol. 22(2), pp. 104-113) features the results of a 2-arm prospective clinical trial in postmenopausal women at risk for cardiovascular disease (CVD), suggesting that patients exhibited a greater improvement in established cardiovascular health markers when comparing Metagenics' FirstLine Therapy(R) therapeutic lifestyle program (FLT) -- to a standard American Heart Association dietary plan (AHAD) and exercise.
- Study Suggests Metagenics' FirstLine Therapy Lifestyle Program Better Than AHA Diet to Reduce Cardiovascular Disease Risks in Postmenopausal Women
February issue of the journal Nutrition (Vol. 22(2), pp. 104-113) features the results of a 2-arm prospective clinical trial in postmenopausal women at risk for cardiovascular disease (CVD), suggesting that patients exhibited a greater improvement in established cardiovascular health markers when comparing Metagenics' FirstLine Therapy(R) therapeutic lifestyle program (FLT) -- to a standard American Heart Association dietary plan (AHAD) and exercise.
- Study Review Shows CoQ10 and Pine Bark Synergistically Enhance Cardiovascular Health
Assessment published in the February issue of Evidence Based Integrative Medicine observes that patients who supplemented with the pine tree bark extract known as Pycnogenol® and CoQ10 in combination benefited from the collaborative antioxidant effects.
- Study Review Shows CoQ10 and Pine Bark Synergistically Enhance Cardiovascular Health
Assessment published in the February issue of Evidence Based Integrative Medicine observes that patients who supplemented with the pine tree bark extract known as Pycnogenol® and CoQ10 in combination benefited from the collaborative antioxidant effects.
- Study Review Shows CoQ10 and Pine Bark Synergistically Enhance Cardiovascular Health
Assessment published in the February issue of Evidence Based Integrative Medicine observes that patients who supplemented with the pine tree bark extract known as Pycnogenol® and CoQ10 in combination benefited from the collaborative antioxidant effects.
- Study Review Shows CoQ10 and Pine Bark Synergistically Enhance Cardiovascular Health
Assessment published in the February issue of Evidence Based Integrative Medicine observes that patients who supplemented with the pine tree bark extract known as Pycnogenol® and CoQ10 in combination benefited from the collaborative antioxidant effects.
- Study Review Shows CoQ10 and Pine Bark Synergistically Enhance Cardiovascular Health
Assessment published in the February issue of Evidence Based Integrative Medicine observes that patients who supplemented with the pine tree bark extract known as Pycnogenol® and CoQ10 in combination benefited from the collaborative antioxidant effects.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- UC Davis Study Shows Grape Seed Extract May Be Effective in Reducing Blood Pressure
One month study was done on 24 male and female patients diagnosed with metabolic syndrome indicates that supplementation with new patent-pending grape seed extract developed and made by Polyphenolics correlates with reduced blood pressure and at higher concetrations, a drop in serum oxidized LDL cholesterol levels was observed.
- UC Davis Study Shows Grape Seed Extract May Be Effective in Reducing Blood Pressure
One month study was done on 24 male and female patients diagnosed with metabolic syndrome indicates that supplementation with new patent-pending grape seed extract developed and made by Polyphenolics correlates with reduced blood pressure and at higher concetrations, a drop in serum oxidized LDL cholesterol levels was observed.
- UC Davis Study Shows Grape Seed Extract May Be Effective in Reducing Blood Pressure
One month study was done on 24 male and female patients diagnosed with metabolic syndrome indicates that supplementation with new patent-pending grape seed extract developed and made by Polyphenolics correlates with reduced blood pressure and at higher concetrations, a drop in serum oxidized LDL cholesterol levels was observed.
- UC Davis Study Shows Grape Seed Extract May Be Effective in Reducing Blood Pressure
One month study was done on 24 male and female patients diagnosed with metabolic syndrome indicates that supplementation with new patent-pending grape seed extract developed and made by Polyphenolics correlates with reduced blood pressure and at higher concetrations, a drop in serum oxidized LDL cholesterol levels was observed.
- UC Davis Study Shows Grape Seed Extract May Be Effective in Reducing Blood Pressure
One month study was done on 24 male and female patients diagnosed with metabolic syndrome indicates that supplementation with new patent-pending grape seed extract developed and made by Polyphenolics correlates with reduced blood pressure and at higher concetrations, a drop in serum oxidized LDL cholesterol levels was observed.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin
Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs.
- New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin
Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs.
- New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin
Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs.
- New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin
Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs.
- New Data Demonstrates Minimal Interactions Between Omacor(R) (Omega-3-Acid Ethyl Esters) and Simvastatin
Data in the July edition of the Journal of Clinical Pharmacology indicates that co-administration of Omacor (omega-3-acid ethyl esters) (4 g) with simvastatin (80 mg) has minimal interaction between the two drugs.
- Results of Jarrow Formulas’ Co-Q10 Study Published in European Heart Journal
The results of a clinical trial investigating the effects of Jarrow Formulas® Q-absorb(TM)on chronic heart failure patients was recently published in the European Heart Journal. In the study, Italian scientists from the Lancisi Heart Institute and the University of Ancona (Institute of Biochemistry) measured the effects of 300 mg per day (100 mg T.I.D.) Q-absorb(TM) on the cardiovascular functional capacity of 23 heart patients.
- Results of Jarrow Formulas’ Co-Q10 Study Published in European Heart Journal
The results of a clinical trial investigating the effects of Jarrow Formulas® Q-absorb(TM)on chronic heart failure patients was recently published in the European Heart Journal. In the study, Italian scientists from the Lancisi Heart Institute and the University of Ancona (Institute of Biochemistry) measured the effects of 300 mg per day (100 mg T.I.D.) Q-absorb(TM) on the cardiovascular functional capacity of 23 heart patients.
- Results of Jarrow Formulas’ Co-Q10 Study Published in European Heart Journal
The results of a clinical trial investigating the effects of Jarrow Formulas® Q-absorb(TM)on chronic heart failure patients was recently published in the European Heart Journal. In the study, Italian scientists from the Lancisi Heart Institute and the University of Ancona (Institute of Biochemistry) measured the effects of 300 mg per day (100 mg T.I.D.) Q-absorb(TM) on the cardiovascular functional capacity of 23 heart patients.
- Study shows unique garlic product works like the real thing
A study presented at the Annual Meeting of the American College of Nutrition today suggests that a new proprietary garlic product developed by Nutra Products, Inc., Garli-Eze®, delivers allicin, the key bioactive ingredient of garlic, to the body in amounts equal to that of fresh high allicin garlic macerate and yielded no unsocial responses due to chewing fresh garlic.
- Study shows unique garlic product works like the real thing
A study presented at the Annual Meeting of the American College of Nutrition today suggests that a new proprietary garlic product developed by Nutra Products, Inc., Garli-Eze®, delivers allicin, the key bioactive ingredient of garlic, to the body in amounts equal to that of fresh high allicin garlic macerate and yielded no unsocial responses due to chewing fresh garlic.
- Study shows unique garlic product works like the real thing
A study presented at the Annual Meeting of the American College of Nutrition today suggests that a new proprietary garlic product developed by Nutra Products, Inc., Garli-Eze®, delivers allicin, the key bioactive ingredient of garlic, to the body in amounts equal to that of fresh high allicin garlic macerate and yielded no unsocial responses due to chewing fresh garlic.
- Study shows unique garlic product works like the real thing
A study presented at the Annual Meeting of the American College of Nutrition today suggests that a new proprietary garlic product developed by Nutra Products, Inc., Garli-Eze®, delivers allicin, the key bioactive ingredient of garlic, to the body in amounts equal to that of fresh high allicin garlic macerate and yielded no unsocial responses due to chewing fresh garlic.
- Clinical Trial Shows Liquid Eggs Enriched With Omega-3 Deliver Heart Health Benefits
Results of a clinical trial published this month in Food Research International indicate that eating omega-3 enriched liquid eggs can improve blood triglyceride levels, boost heart health, and help families reach their daily recommended intake of omega-3.
- Clinical Trial Shows Liquid Eggs Enriched With Omega-3 Deliver Heart Health Benefits
Results of a clinical trial published this month in Food Research International indicate that eating omega-3 enriched liquid eggs can improve blood triglyceride levels, boost heart health, and help families reach their daily recommended intake of omega-3.
- Clinical Trial Shows Liquid Eggs Enriched With Omega-3 Deliver Heart Health Benefits
Results of a clinical trial published this month in Food Research International indicate that eating omega-3 enriched liquid eggs can improve blood triglyceride levels, boost heart health, and help families reach their daily recommended intake of omega-3.
- Clinical Trial Shows Liquid Eggs Enriched With Omega-3 Deliver Heart Health Benefits
Results of a clinical trial published this month in Food Research International indicate that eating omega-3 enriched liquid eggs can improve blood triglyceride levels, boost heart health, and help families reach their daily recommended intake of omega-3.
- Study Sheds Light on Soy and Heart Health
According to a study published in the journal Maturitas, Chilean researchers recruited post-menopausal women to take part in the double-blind, randomized, placebo-controlled study, randmoly assigning participants to receive a daily supplement of 100 mg isoflavones or an identical placebo for three months. At the end of the three-month period, the group receiving the isoflavone supplement showed a significant decrease in the density of a particular platelet receptor (known as TxA2), while the placebo group remained mostly unchanged.
- Study Sheds Light on Soy and Heart Health
According to a study published in the journal Maturitas, Chilean researchers recruited post-menopausal women to take part in the double-blind, randomized, placebo-controlled study, randmoly assigning participants to receive a daily supplement of 100 mg isoflavones or an identical placebo for three months. At the end of the three-month period, the group receiving the isoflavone supplement showed a significant decrease in the density of a particular platelet receptor (known as TxA2), while the placebo group remained mostly unchanged.
- Study Sheds Light on Soy and Heart Health
According to a study published in the journal Maturitas, Chilean researchers recruited post-menopausal women to take part in the double-blind, randomized, placebo-controlled study, randmoly assigning participants to receive a daily supplement of 100 mg isoflavones or an identical placebo for three months. At the end of the three-month period, the group receiving the isoflavone supplement showed a significant decrease in the density of a particular platelet receptor (known as TxA2), while the placebo group remained mostly unchanged.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Green Bay, WI (July 13, 2006) – EuroPharma’s president, Terry Lemerond, recently obtained the North America distribution rights to a revolutionary Omega -3 phospholipid complex with DHA/EPA, called Vectomega®. Molecularly different from other omega-3’s on the market, this new complex is 50 times more absorbable across cellular membranes than other DHA/EPA products and is available as a water/oil soluble powder.
Now, preliminary findings from a recent human trial by French doctors demonstrate that only 2 tablets per day of Vectomega® improve cardiovascular health by reducing cholesterol, triglycerides and increasing HDL-c in a healthy population, among other benefits.
The extensive criteria studied make it possible to envision a wide range of health concerns in which Vectomega®’s phospholipids can be of benefit. In addition to cardiovascular support, it also shows positive activity in the area of cellular aging, memory, sleep quality, physical recovery, and many other areas of anti-aging. Clinical tolerance in this trial was excellent; no side effects were reported; specifically no eructation, and no reflux of fish taste. The study population was forty healthy volunteers followed for 60 days, and compliance was 100%. Dosage was one 300 mg tablet two times daily. Food habits were not modified.
Omega 3 fish oils used for its DHA/EPA have become increasingly popular in response to a growing body of science on its health benefits, yet few products have risen above the pack. Vectomega®’s superior bioavailability, rapidly noticed results, and the novel dosage form are about to change that.
Vectomega® is a natural marine complex made up of five different phospholipids, DHA and EPA, along with proteins and amino acids as they occur in nature. Vectomega® uses a biological innovation that extracts naturally occurring marine phospholipids with the omega-3 fatty acids, EPA and DHA. Standard fish oil products do not contain these marine phospholipids. This patented innovation, called vectorization, uses a gentle, cold water and enzyme process avoiding heat, solvents, and chemical modifications unlike the process utilized by standard fish oil products.
“The results from this latest trial support previous findings and prove that Vectomega® has optimal bioavailability and works on a cellular level. My decades of experience in the supplements industry tells me this is destined to hold a prime position in the fight against anti-aging and to support optimal health at all levels,” stated Terry Lemerond, president of EuroPharma. “Vectomega® surpasses other DHA/EPA products in terms of bioavailability, absorption and efficacy. Additionally, because it is a water and oil soluble powder, Vectomega® can be applied to any commercial food or dietary supplement formulation to dramatically increase its market potential.”
Vectomega®’s phospholipid vectorization has been clinically demonstrated to have superior bioavailability compared to standard fish oil products. In technical terms, the amphiphilic properties of the marine phospholipids can easily cross the hydrophilic membrane barriers for superior bioabsorption compared to “neutrally charged” commercial fish oils on the market today. Research has confirmed that 50 times more Vectomega® DHA and EPA crosses the cell membrane as compared to standard commercial fish oil products.
At the therapeutic dose, 2 tablets (600 mg) of Vectomega® are equal to 16 capsules (7,200 mg) of standard fish oil. Research has shown that because Vectomega®’s marine phospholipids are vectorized with DHA and EPA in a specific location on the carbon chain (Sn-2 on the glycerol), Vectomega® is 50 times more absorbable via cell membranes.
EuroPharma offers Vectomega® in raw material or finished tablet form, manufacturers seeking more information on availability and pricing should contact Lisa Joski at Ljoski@EuroPharmaUSA.com, 920-406-6500 or visit www.EuroPharmaUSA.com.
EuroPharma, Inc. a Green Bay, Wisconsin-based supplier offers Vectomega® and other truly unique and industry changing ingredients. EuroPharma’s president, Terry Lemerond has over 40 years of industry experience and product development expertise. Lemerond’s background, knowledge, and associations with respected doctors and scientists worldwide allow him continuous access to proven formulas and ingredients that have yet to be introduced to the world or to the U.S. market.
-- END –
Contact: Lisa Joski 920-406-6506
Ljoski@EuroPharmaUSA.com |